Plains Resources News

A webcast of this presentation will be available at www.protalix.com on the event calendar page and a replay will be archived and available after the conference for 30 days.

It was midnight when an anxious Ari Zimran finally got the phone call for which he had been waiting.

This week , the US Food and Drug Administration approved the first drug for humans produced by a genetically modified plant.

Several other analysts have also recently commented on the stock. Analysts at Oppenheimer raised their price target on shares of Protalix BioTherapeutics from $9.00 to $11.00 in a research note to investors on Wednesday.

When there's something worth discussing - and there usually is - I like to review some of the activity my colleagues from Seeking Alpha pointed out on SA and across the Web.

HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia Pfizer Inc.

Protalix BioTherapeutics, Inc. , announced today the Company has scheduled a conference call and webcast for Wednesday, May 2, 2012 at 8:00 AM EDT to review the U.S. Food and Drug Administration's approval of ELELYSO for the treatment of Type 1 Gaucher disease.

The U.S. Food and Drug Administration today approved Elelyso for long-term enzyme replacement therapy to treat a form of Gaucher disease, a rare genetic disorder.

U.S. drug regulators gave the nod to Protalix Biotherapeutics Inc and Pfizer Inc's experimental biotech drug for the rare genetic disease Gaucher.

April 29--Trading in shares of Protalix Biotherapeutics Inc. has been heavy in recent weeks, ahead of a decision by US Food and Drug Administration whether to approve the company's treatment for Gaucher's disease Uplyso.

Protalix BioTherapeutics opened at 6.99 on Monday. Protalix BioTherapeutics has a 52-week low of $4.06 and a 52-week high of $7.33. The company's market cap is $634.8 million.